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Objective: This study examined the reproducibility of speed corresponding to specific lactate markers 
during incremental treadmill running of normal and prolonged stage durations. Design: Nineteen 
healthy participants (14 male, 5 female) performed repeated, incremental treadmill running trials of 4 
and 8 min stages on separate days to examine the test-retest reproducibility of speed at lactate markers. 
Two trials were completed for each duration in a randomised order. Method: Fingertip blood samples 
drawn upon stage completion were analysed for plasma lactate, then used to determine running speed 
at: 2.0, 3.5, and 4.0 mmol·l-1 fixed blood lactate accumulations (FBLA), a 1 mmol·l-1 rise from 
baseline, and the markers: the deviation maximum (Dmax), the Dmax of the second curve derivative 
(D2Lmax), the lactate threshold (LT) and log-log LT. Results:  The 2.0 mmol·l-1 FBLA reported the 
lowest mean bias between 4 min trials (-0.06 km·h-1), with the narrowest limits of agreement (LoA) (-
1.78 to 1.66 km·h-1). The Dmax had the second lowest bias (0.14 km·h-1), D2Lmax the second narrowest 
LoA (-1.93 to 2.90 km·h-1). For 8 min stages, the 1 mmol·l-1 rise demonstrated, low mean bias (-0.13 
km·h-1) and narrowest LoA (-1.22 to 0.97 km·h-1) between trials. Conclusions: This preliminary report 
suggests the reproducibility of running speed at lactate summary markers is influenced by stage 
duration for incremental treadmill running. Varied marker reproducibility between 4 and 8 min stages 
indicates different blood lactate response, and therefore workload calculation, according to stage 
length. Consideration of marker construct is recommended. 
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i. Introduction 
Incremental exercise with blood sampling to characterise the lactate-workload relationship is 
commonplace to determine exercise intensity and monitor training adaptation.1 Following endurance 
training, attenuated lactate response during submaximal exercise results from diminished lactate 
production at low-, and increased lactate removal at high-workloads.2 Compared to maximal oxygen 
uptake ( O2max), lactate measurement allows greater sensitivity to identify change in training status3 
and can be determined during submaximal incremental exercise.1 The lactate-workload relationship 
during incremental exercise can be summarised using lactate markers and the lactate threshold (LT). 
The LT signifies a metabolic breakpoint, above which, the contribution of anaerobic glycolysis 
becomes significant to maintain ATP resynthesis.4 Furthermore, lactate clearance rate appears limited 
at workloads approaching LT.5 Lactate response is influenced by the blood sampling site,6 in 
particular, venous blood has been seen to overestimate workload during short stage increments.7 To 
characterise a curvilinear blood lactate response, various endurance markers and single summary 
statistics have been proposed.8 Given the ease with which lactate can be measured, it is important to 
recognise the associated measurement error for a particular marker and how this influences the lactate-
workload relationship for incremental exercise. 
 
Using repeated measurements during incremental treadmill running of 3 min stages, fixed blood 
lactate accumulations (FBLA) (e.g., 4.0 mmol·l-1) have demonstrated good reproducibility (r = 0.95).9 
However, comparison of test-retest measures used correlation coefficients. While these describe 
relationship, they do not indicate agreement and cannot detect systematic error. Applying correlation 
coefficients, limits of agreement (LoA) and 95% confidence intervals (CI) to treadmill speeds at 4.0 
mmol·l-1 FBLA and LT for 4 min stages, Grant et al.10 reported strong relationship, but poor inter-trial 
reproducibility. In addition to highlighting the importance of supplementing correlation coefficient 
analysis with LoA, these results also suggest greater reproducibility for individuals of greater aerobic 
fitness. Reproducibility of the 4.0 mmol·l-1 marker has also been reported for repeated incremental 
running11 and cycling trials.12 Recently, the measurement error of several markers was examined for 
the lactate-power relationship during incremental cycling of 3 min stages.13 Of several markers only 
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the deviation maximum (Dmax) exhibited adequate reproducibility (coefficient of variation (CV) = 
3.8%, intraclass correlation coefficient (ICC) r = 0.90, CI width = 31.8 W). Given that blood lactate 
may not stabilise within 4 min, investigations concerning marker reliability for longer stages remains 
scant. 
 
Use of 3 to 5 min stage increments is based upon the attainment of oxygen uptake and heart rate 
steady state; yet blood lactate likely requires greater duration to achieve stable concentrations. Bentley 
et al.14 found similar cycling workloads at lactate markers between 3 and 8 min stage increments. Yet, 
stages beyond 6 min are recommended to avoid delay in blood lactate response to running 
increments.15 Insofar as both studies were limited to measures at a 4.0 mmol·l-1 FBLA and the LT, we 
assessed the reliability of various markers. Extending upon findings of Bentley14 and Kuipers,15 we 
examined the reproducibility of speed at lactate summary markers using incremental treadmill running 
of traditional, 4 min, and prolonged, 8 min stage durations. 
 
ii. Methods 
Nineteen healthy participants (14 male, 5 female; age 22.7 ± 3.8 years; height 174.9 ± 8.0 cm; body 
mass 69.0 ± 10.0 kg) provided written informed consent. Volunteers completed a medical, and long 
International Physical Activity Questionnaire;16 thereby conforming to high levels of habitual physical 
activity (male, 2855.5 ± 1359.8 MET·min-1/wk-1; female, 3224.3 ± 1013.0 MET·min-1/wk-1). The 
investigation was approved by the University of Chichester Ethics Committee. 
 
Five laboratory visits included: one familiarisation, and two repeated incremental running trials of 4 
and 8 min stages to volitional exhaustion on separate days. The familiarisation involved two 
submaximal stages (e.g., 8 and 9 km·h-1) of 4 min followed, after a 15 min rest, by two of 8 min. 
Blind-selection was used to randomly allocate trial order, and testing was completed within a four 
week period (range of two to eight days between repeated trials). Participants were requested to arrive 
hydrated and refrain from strenuous exercise 24 h prior. All wore the same footwear for each trial. 
Testing occurred between 09:00 and 14:00 h, with each participant reporting to laboratory at the same 
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time of day for each trial. The same pre-calibrated powered treadmill (Woodway Ergo ELG 70, 
Woodway, Weil am Rhein, Germany) was used for all trials in a temperature controlled laboratory 
(19–22°C). Participants were instructed to maintain and self-record habitual diet and physical 
activities 48 h prior to the first trial; arriving 3 h after their last meal and caffeine intake. These records 
were prescribed in the 48 h preceding all subsequent trials. Resting blood glucose was similar between 
trials (p > 0.05).  
 
Each session began with the explanation of experimental protocol, with anthropometric data collected 
during the familiarisation. Height was recorded with using a free-standing stadiometer (Holtain Ltd., 
Crymych, UK) and body mass with digital health scales (Seca Ltd., Birmingham, UK). Fingertip 
capillary blood was sampled in the final 30 s of a 5 min seated rest; extracted plasma was then 
measured for lactate. Participants warmed up on a treadmill at a 1% gradient for 5 min at: 7 km·h-1 for 
females, and 8 km·h-1 for males. These speeds were selected to commence trials thereafter, as no 
participant conformed to being endurance trained. All testing began with participants lowering 
themselves onto a moving treadmill belt set at the required starting speed. Modified from previous,15 
participants completed submaximal stages with 1 km·h-1 speed increments every 4 min (first trial, 7 ± 
1 stages (range 6 to 10); second trial, 7 ± 1 stages (range 6 to 10)) or 8 min (first trial, 5 ± 1 stages 
(range 5 to 8); second trial, 5 ± 1 stages (range 5 to 8)). A further two individuals participated, but 
were excluded from analysis as they failed to complete sufficient trial stages. The investigator 
provided verbal encouragement and feedback on time remaining during the final minute of each stage. 
Upon stage completion participants were instructed to straddle the treadmill for ~30 s as speed was 
increased. Maximal running speed was taken as the last completed stage. 
 
Capillary blood samples (25 µl) were drawn from the right index finger into EDTA-coated microvettes 
(Sarstedt Aktiengesellschaft & Co., Nümbrecht, Germany) at rest and during the final 30 s of each 
stage. Blood samples were analysed immediately in duplicate for plasma lactate (2300 STAT Plus™ 
analyser, YSI Life Sciences, Yellow Springs, USA), with pre-test calibration to standard lactate 
concentrations of 2.5 and 7.5 mmol·l-1. When a test-retest difference less than 0.4 mmol·l-1 was 
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measured, the mean was recorded; when a difference greater than 0.4 mmol·l-1 was measured, a third 
analysis was run with the mean of the two closest samples recorded.10 Lactate analysis software8 
employing 3rd degree polynomial fitting (r2 = 0.983 ± 0.030) was used to determine running speed at 
the fixed markers: 2.0, 3.5, and 4.0 mmol·l-1, the 1 mmol·l-1 rise from baseline, and the markers: Dmax, 
the Dmax of the second curve derivative (D2Lmax), LT and log-log LT. In addition, the lactate-speed 
relationship was constructed for each trial completed by the participants. The Dmax was the speed at the 
maximum perpendicular from a line connecting the first and the final lactate-speed points to the 
polynomial,17 with the D2Lmax derived from the maximum acceleration of the lactate curve.18 The LT 
method employed a ‘broken stick’ model,19 identifying the dividing point between two fitted 
regression lines as the corresponding speed, with log-log LT applying a log transformation.20 
 
Mean speed for repeated trials was compared between 4 and 8 min using Paired t-tests. Speed at 
lactate markers for incremental running of 4 and 8 min stages were analysed using: Bland and 
Altman’s 95% LoA,21 and Deming regression.22 Typical error (mean bias SD divided by the square 
root; Table 1) and 95% CI of mean bias and LoA (selectively reported) were also calculated. Absolute 
values are presented as heteroscedasticity was absent in the data. Statistical analyses were calculated 
using GraphPad Prism 5 for Windows (GraphPad Software, Inc., California, USA), with statistical 
significance accepted as p < 0.05. 
 
iii. Results 
There was no effect of duration on speed at fixed markers, but lower speeds were seen for 8 min stages 
at Dmax (-1.7 km·h-1), LT (-0.8 km·h-1) and log-log LT (-0.8 km·h-1) markers (p < 0.05). The 2.0 
mmol·l-1 FBLA reported the lowest mean bias between 4 min trials (-0.06 km·h-1) with the narrowest 
LoA (-1.78 to 1.66 km·h-1; Figure 1). The Dmax had the second lowest bias (0.14 km·h-1), but widest 
LoA (-3.77 to 4.04 km·h-1). The D2Lmax had high mean bias (0.48 km·h-1), with narrow LoA (-1.93 to 
2.90 km·h-1). For D2Lmax, 95% CI were wide for lower (-2.96 to -0.90 km·h-1) and upper limits (1.87 
to 3.93 km·h-1). Mean bias was 0.31 km·h-1 (LoA, -2.25 to 2.87 km·h-1) for LT, and -0.25 km·h-1 (LoA, 
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-3.12 to 2.62 km·h-1; Table 1) for the 1 mmol·l-1 baseline rise. The log-log LT had large mean bias 
(0.44 km·h-1), and wide LoA (-2.23 to 3.12 km·h-1). 
 
<<< TABLE 1 HERE >>> 
 
<<< FIGURE 1 HERE >>> 
 
Between 8 min trials, the 1 mmol·l-1 baseline rise displayed a -0.13 km·h-1 mean bias, with LoA -1.22 
(95% CI, -1.71 to -0.73 km·h-1) to 0.97 km·h-1 (95% CI, 0.48 to 1.46 km·h-1; Figure 2). The D2Lmax 
had a -0.48 km·h-1 mean bias, with LoA from -2.63 to 1.67 km·h-1. Mean bias between 8 min trials for 
the LT were 0.19 km·h-1 (LoA, -2.03 to 2.41 km·h-1), and for the log-log LT -0.07 km·h-1 (LoA, -2.32 
to 2.18 km·h-1). The 4.0 mmol·l-1 FBLA showed moderate inter-trial agreement (mean bias, -0.19 
km·h-1; LoA, -2.59 to 2.22 km·h-1). The Dmax reported large mean difference (-0.79 km·h-1) and widest 
LoA (-3.59 to 2.00 km·h-1). 
 
Between 4 min, Deming regression slopes (95% CI) were: 1.05 (0.32 to 1.78 km·h-1; 2.0 mmol·l-1 
FBLA), 0.92 (0.30 to 1.54 km·h-1; 3.5 mmol·l-1 FBLA), 0.94 (0.42 to 1.47 km·h-1; 4.0 mmol·l-1 
FBLA), 1.19 (0.54 to 1.84 km·h-1; 1 mmol·l-1 baseline rise), 0.72 (-0.13 to 1.56 km·h-1; Dmax), 0.82 
(0.46 to 1.20 km·h-1; D2Lmax), 1.1 (0.38 to 1.82 km·h-1; LT) and 0.32 (0.27 to 2.21 km·h-1; log-log 
LT). Between 8 min, slopes (95% CI) were: 0.84 (0.48 to 1.20 km·h-1; 2.0 mmol·l-1 FBLA), 1.27 (0.70 
to 1.86 km·h-1; 3.5 mmol·l-1 FBLA), 1.22 (0.81 to 1.62 km·h-1; 4.0 mmol·l-1 FBLA), 0.98 (0.78 to 1.19 
km·h-1; 1 mmol·l-1 baseline rise), 1.77 (0.30 to 3.24 km·h-1; Dmax), 1.80 (0.86 to 2.80 km·h-1; D2Lmax), 
0.44 (0.15 to 0.73 km·h-1; LT) and 0.60 (-0.05 to 1.24 km·h-1; log-log LT). Typical error ranged from 
0.39 to 1.41 km·h-1 for both 4 and 8 min trials (Table 1). 
 
<<< FIGURE 2 HERE >>> 
 
iv. Discussion 
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This preliminary report suggests the reproducibility of running speed at lactate summary markers is 
influenced by stage duration for incremental treadmill running. All markers were more reproducible 
for the prolonged, 8 min stages, when compared to 4 min. For 4 min trials, a 2.0 mmol·l-1 FBLA 
appeared most reproducible, and for 8 min trials, the 1 mmol·l-1 baseline rise. Regardless of stage 
duration, the Dmax demonstrated poor reproducibility. If a stimulus, such as treadmill speed, fails to 
elicit reproducible physiological response between test-retest trials, change cannot be reliably 
quantified. Using LoA, cycling workload at a 4.0 mmol·l-1 FBLA has showed agreement with Dmax (-
12.2 ± 29.1 W), but not with single (78.8 ± 44.9 W) or double breakpoint models (-21.1 ± 79.5 W).23 
Elsewhere, Pfitzinger and Freedson24 reported strong inter-trial relationship between speed and various 
fixed lactate markers (from r = 0.98 to 0.99), with 5 min stages for endurance trained men. 
Furthermore, the reliability coefficient of the FBLA 4.0 mmol·l-1 was observed as r = 0.92 for trained 
and r = 0.55 for untrained women.25 Supporting the assertion that the variance between test-retest trials 
may be greater among sedentary, than trained individuals. Superior hydrogen ion buffering capacity 
seen for well-trained individuals (team-sport athletes, but not necessarily endurance-trained athletes)26 
may delay metabolic acidosis at given running speeds; in turn, prolonging maximal exercise duration. 
Alongside relative biological and motivational homogeneity in trained subjects, this may diminish the 
inter-test variability herein. Grant et al.10 considered the fitness levels, classifying participants as unfit 
or moderately fit according to speed at the first rise from baseline. Narrower LoA were reported for 
those attaining the LT at speeds greater than 10.5 km·h-1. We did not examine fitness, but our LT LoA 
for 4 min trials (-2.25 to 2.87 km·h-1) can be interpreted as follows: if LT was reached at 12 km·h-1 
during the first trial, with the same trial repeated two to eight days later, their LT could range from 
9.75 to 14.87 km·h-1. For 8 min protocols, the repeated trial LT could be as low as 9.97 km·h-1, and as 
high as 14.41 km·h-1.  
 
Prolonging stage duration has the effect of reducing both running speed at the FBLA 4.0 mmol·l-1, and 
the number of stages performed above the anaerobic threshold.11 Longer stages may decrease variance 
in speed at particular markers between test-retest trials. It is likely that prolonged stages allow 
stabilisation between arterial and muscle lactate concentrations, facilitating lactate steady state, thus 
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limiting differences in lactate diffusion capacity for the sprint and endurance trained. Fixed blood 
lactate markers appeared consistently agreeable across 4 and 8 min stages, whereas the Dmax and 
D2Lmax were prone to stage length. Unlike Dmax, estimated from first and final lactate concentrations; 
D2Lmax is the mathematically-derived, second maximal derivative accounting for final lactate. This, in 
part, may explain the greater 8 min trial reproducibility seen for D2Lmax in comparison to Dmax. 
Prolonged stages may cause insufficient increase in lactate between first and final workloads to fit 
polynomial regression, but not at the point of maximum acceleration. Longer stages may reduce the 
number of lactate samples, presenting unsatisfactory model-fitting using linear regression.20 Based on 
five samples, each regression line would consist of two points; resulting in inaccurate and poor 
threshold reproducibility. Outliers would induce even greater variability in workload estimation. 
Criterion measures are often validated during maximal lactate steady state (MLSS) tests, with 
individuals sustaining marker speed for extended periods. The MLSS was not our experimental aim, 
but should be considered for marker validation studies.  Even using the 1 mmol·l-1 baseline rise, a 2.19 
km·h-1 change in running speed would be required to be deemed training-induced. 
 
Fixed blood lactate markers do not account for the individual variation in lactate response to exercise. 
However, workloads derived from the Dmax, D2Lmax, LT and log-log LT are dependent upon the nature 
of the underlying lactate curve.8 Of these markers, the D2Lmax was more reproducible for 4 min stages, 
and similar reproducibility was seen between D2Lmax, the LT and log-log LT for 8 min stages. 
Elsewhere, the Dmax has been found to correlate favourably with endurance performance in trained 
runners27 and cyclists,28 representing good reproducibility for incremental cycling exercise.13 In 
contrast, we found speed at Dmax to be unstable between trials. Mean bias was low (0.14 km·h-1), but 
95% of trial differences resided within a -3.77 to 4.04 km·h-1 range for 4 min trials. Of seven markers, 
Morton et al.13 found the Dmax to have the highest ICC (0.903), and the narrowest CI width (31.8 W) 
for cycling power output. However, as all subsequent trials were terminated at the maximum workload 
achieved in trial one; the reliability of markers dependent upon peak power may have been inflated. 
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The LT appeared more stable across 4 and 8 min stages, in comparison to Dmax, D2Lmax and log-log 
LT.  Deming regression revealed no proportional or systematic bias between repeated trials of 4 or 8 
min. The LT at 8 min stages exhibited the lowest regression slope (0.44), and a narrow 95% CI range 
defined by 0.15 to 0.73 km·h-1. This may indicate less susceptibility to blood lactate outliers sampled 
for 8 min stages. Higher intensity markers, such as the LT, may better reflect the aerobic-anaerobic 
transition, assuming lactate responds exponentially to increasing workload. Earlier studies by Foxdal 
and colleagues29 examined the effect of incremental stage duration on blood lactate concentration and 
the corresponding validity to predict endurance performance.30 Stages of 4 and 6 min tended to 
overestimate MLSS when using the FBLA 4.0 mmol·l-1, in comparison to 8 min stages. Of methods 
examined, 0.9 km·h-1 increments every 8 min with haemolysed capillary sampling was proposed the 
most accurate predictor of maximal endurance running velocity. However, longer stages may 
demotivate, evoke premature fatigue and compromise assessment of peak measures. Equally, the 
reduced laboratory times, and swift analyses for fixed markers, make shorter tests appealing to 
coaches and athletes. That venous blood lactate may not achieve steady state within 8 min has been 
contested.15 Measuring FBLA 4.0 mmol·l-1 for incremental treadmill running of 1, 3 and 6 min stages, 
these authors argued for the use of stages exceeding 6 min. Faster mean running speed at FBLA 4.0 
mmol·l-1 was reported for 3 min (14.4 km·h-1), in comparison to 6 min (12.9 km·h-1) stages. However, 
a delayed venous blood lactate response was observed for the respective running speed that was absent 
for 6 min stages.  
 
v. Conclusions 
To be deemed reliable, a marker must demonstrate adequate reproducibility across test-retest sessions.  
In this pilot study, the reproducibility of running speed at various lactate summary markers may be 
influenced by stage duration during incremental treadmill running. Greater reproducibility for 8 min, 
as opposed to 4 min stage trials, is likely attributable to, a) reduced workloads at and beyond the 
anaerobic threshold, and b) greater duration to attain lactate steady state in capillary blood. However, 
moderate stages allow a) more increments for sampling, therefore b) greater exercise intensities, and c) 
sufficient time for muscle-to-blood lactate equilibrium.  
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vi. Practical Applications 
This pilot study suggests for future studies to examine lactate marker reproducibility in trained 
individuals and/or larger cohorts: 
 
• 8 min stages offer more reliable measures of lactate markers, in comparison to 4 min stages during 
treadmill running. 
• Varied marker reproducibility between 4 and 8 min stages indicates different blood lactate 
response, and therefore workload calculation, according to stage length. Consideration of marker 
construct is recommended. 
• Future research is required to advance these findings to larger cohort of endurance trained athletes 
enabling a more refined analysis of lactate marker reliability. 
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ix. Table legend 1 
Table 1 Mean bias and absolute limits of agreement for blood lactate markers during repeated 2 
incremental exercise trials of 4 and 8 min stages (values presented as km∙h-1). 3 
 4 
x. Figure legends 5 
Figure 1 Bland-Altman plot of mean bias and absolute limits of agreement of speed at the 2.0 mmol·l-6 
1 fixed blood lactate accumulation between first and second trials of incremental treadmill running of 7 
4 min stages (dotted lines: 95% limits of agreement). 8 
 9 
Figure 2 Bland-Altman plot of mean bias and absolute limits of agreement of speed at the 1 mmol·l-1 10 
rise from baseline between first and second trials of incremental treadmill running of 8 min stages 11 
(dotted lines: 95% limits of agreement) (n = 18; data point excluded where blood lactate response did 12 
not satisfy marker criteria for speed calculation). 13 
